Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$195.45 USD

195.45
3,453,379

-1.37 (-0.70%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why AbbVie (ABBV) Could Beat Earnings Estimates Again

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

Sweta Killa headshot

Healthcare ETFs in Focus as Q2 Earnings Unfold

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars

Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.

Pfizer (PFE) Inks Vaccine Deal, Faces FDA Delay on JAK Drugs

Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Here's Why AbbVie (ABBV) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.

Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA

The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.

J&J (JNJ) Beats on Q2 Earnings & Sales, Ups View, Stock Rises

J&J (JNJ) beats second-quarter 2021 estimates for both earnings and sales. It raises its financial expectations for the year. It forecasts $2.5 billion in 2021 sales of COVID-19 vaccine.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $115.42, marking a -1.77% move from the previous day.

AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA

The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis.

Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA

The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.

The Zacks Analyst Blog Highlights: JPMorgan, Goldman Sachs, Microsoft, AbbVie, and Enbridge

The Zacks Analyst Blog Highlights: JPMorgan, Goldman Sachs, Microsoft, AbbVie, and Enbridge

Sheraz Mian headshot

Q2 Earnings Scorecard & Analyst Reports for Microsoft, AbbVie & Enbridge

We have provided a real-time scorecard of the Q2 earnings season, in addition to featuring Microsoft (MSFT), AbbVie (ABBV), Enbridge (ENB) and other stocks.

AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $117.63, moving +0.9% from the previous trading session.

Kinjel Shah headshot

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)

AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.

Lilly's (LLY) Jardiance Heart Failure Study Meets Main Goal

Lilly's (LLY) Jardiance significantly reduces the risk of the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction.

Kinjel Shah headshot

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season

AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $115.17 in the latest trading session, marking a +0.8% move from the prior day.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

ABBV vs. NVO: Which Stock Is the Better Value Option?

ABBV vs. NVO: Which Stock Is the Better Value Option?